buster 50mg láminas bucodispersables
ctcbio inc. corea, republica de - cada lámina bucodispersable contiene: sildenafilo 50.00 mg - laminas bucodispersables - cada lámina bucodispersable contiene: sildenafilo 50.00 mg
ripol 100 mg lamina orodispersable
laboratorios elmor, s.a. - sildenafil - lamina orodispersable - 100 mg
vascurol 20mg pelicula bucodispersable
farmindustria s.a. - droguerÍa - pelicula bucodispersable - por dosis - - tadalafil
vascurol 5 mg pelicula bucodispersable
farmindustria s.a. - droguerÍa - pelicula bucodispersable - por tableta - - tadalafil
tadt láminas bucodispersables 10 mg
laboratorios recalcine s.a. - tadalafilo - sin formulas
tadt láminas bucodispersables 20 mg (tadalafilo)
laboratorios recalcine s.a. - tadalafilo - sin formulas
tadt láminas bucodispersables 5 mg (tadalafilo)
laboratorios recalcine s.a. - tadalafilo - sin formulas
blincyto
amgen europe b.v. - blinatumomab - leucemia-linfoma linfoblástica de células precursoras - agentes antineoplásicos - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
sincronia 100 mg/20 mg/2,5 mg capsulas duras
new line pharma, s.l. - atorvastatina calcica trihidrato, ramipril, acetilsalicilico acido - excipientes: carboximetilalmidon sodico tipo a,lecitina de soja,xantano, goma de,lactosa monohidrato,almidon pregelatinizado,polisorbato 80,almidon pregelatinizado,fumarato de estearilo y sodio,xantano, goma de,lecitina de soja - agentes modificadores de los lÍpidos, combinaciones - inhibidores de la hmg-coa reductasa, otras combinaciones - atorvastatina, acido acetilsalicilico y ramipril
sincronia 100mg/20mg/10mg capsulas duras
new line pharma, s.l. - atorvastatina calcica trihidrato, acetilsalicilico acido, ramipril - excipientes: carboximetilalmidon sodico tipo a,lecitina de soja,xantano, goma de,lactosa monohidrato,almidon pregelatinizado,polisorbato 80,almidon pregelatinizado,fumarato de estearilo y sodio,xantano, goma de,lecitina de soja - agentes modificadores de los lÍpidos, combinaciones - inhibidores de la hmg-coa reductasa, otras combinaciones - atorvastatina, acido acetilsalicilico y ramipril